Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.
Emerging Treatment Updates: Antibody Drug Conjugates in Relapsed/Refractory Follicular Lymphoma
Read More
Anemia Management in LR-MDS: Treatment Insights From ASH 2024
Emerging Updates in Front-Line Immunotherapy for Unresectable Hepatocellular Carcinoma (uHCC)
SABCS 2024: Updates From Clinical Trials of Elacestrant for ER+/HER2– Metastatic Breast Cancer From SABCS 2024
Updates in EGFR-Mutant Advanced NSCLC – First- and Second-Line Treatment
Beyond the Basics – Lower-Risk Myelodysplastic Syndromes
INVESTIGATOR PERSPECTIVES Application of a Tissue-Free Epigenomic Assay to Improve MRD Detection in Previously Treated CRC
Evolving Landscape of First-Line Therapies in Metastatic RCC: Cabozantinib-Based Approaches
Evolving Role of BTKis in CLL/SLL: Highlights from EHA 2024
Recent Advances for Treating Anemia in Lower-Risk Myelodysplastic Syndromes
Recent Updates in the Treatment Landscape for Advanced Non-Clear Cell Renal Carcinoma
Recent Advances for CAR T- Cell Therapy in R/R Multiple Myeloma
The Evolving Landscape of Non-Clear Cell Renal Cell Carcinoma
Optimizing Therapy for Lower-Risk MDS
PERSEUS Primary Analysis Findings in Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Stem Cell Transplantation
Advancing BTKis in R/R CLL/SLL: Highlights from ASH 2023
Expert Insights into Recent Updates for the Management of Lower-Risk MDS
Emergent Advances and Subgroup Data in ER+, HER2- Metastatic Breast Cancer from SABCS 2023
The Evolving Treatment Landscape in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Managing Myelofibrosis Patients With Anemia
Dialogue in Diagnostics: Optimizing ESR1m Testing in ER+/HER2- Metastatic Breast Cancer
Endometrial Carcinoma Treatment Advances
Renal Cell Carcinoma Treatment Updates from ASCO 2023 and KCRS 2023
Transforming Outcomes: Optimizing Survival, Quality of Life & Treatment Strategies in Advanced RCC
Advances in the First-Line Treatment of Anemia Associated With Lower-Risk Myelodysplastic Syndromes (LR-MDS): Phase 3 COMMANDS Trial Data
Developing Strategies for Myelofibrosis Treatment
Advances in Myelofibrosis Treatment
Understanding Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC)
Metastatic Renal Cell Carcinoma: Updates to CheckMate 9ER and COSMIC-313 Trial Data
Treating Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) with Lenvatinib